Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-ROSETTA-Stroke: Switch to rosuvastatin plus ezetimibe after statin monotherapy in ischemic cerebrovascular disease
KCT0008455Phase 4Completed
- Sponsor
- Samjin Pharmaceutical Co., Ltd.
- Start
- Jul 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rosuvastatin, ezetimibe in dyslipidemia, ischemic stroke, transient ischaemic attack (TIA), cerebral arteriosclerosis, sponsored by Samjin Pharmaceutical Co., Ltd.. Started Jul 2023; status: completed.
02
Drugs
rosuvastatinezetimibe
03
Conditions
dyslipidemiaischemic stroketransient ischaemic attack (TIA)cerebral arteriosclerosis
Beyond the preview
Go deeper on KCT0008455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008455.